Intratracheal administration of recombinant human factor IX (BeneFix™) achieves therapeutic levels in hemophilia B dogs

Thrombosis and Haemostasis

Volumn 85, Issue 3, 2001, Pages 445-449

  Russell, K E ^a   Read, M S ^a   Bellinger, D A ^a   Leitermann, K ^a   Rup, B J ^a   McCarthy, K P ^a   Keith J C , Jr ^a   Khor, S P ^a   Schaub, R G ^a   Nichols, T C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Factor IX; Hemophilia B; Inhalation therapy

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ANIMAL MODEL; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD CLOTTING TIME; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG SCREENING; HEMOPHILIA B; INHALATION; LUNG; NONHUMAN; PRIORITY JOURNAL; SLOW DRUG RELEASE; SYSTEMIC CIRCULATION;

EID: 0035077128     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615602     Document Type: Article

References (30)

1. Extravascular administration of factor IX: Potential for replacement therapy of canine and human hemophilia B
2. Pulmonary delivery of peptides and proteins for systemic action
3. Fate of aerosolized recombinant DNA-produced alpha1-antitrypsin: Use of epithelial surface of the lower respiratory tract to administer proteins of therapeutic importance
4. Recombinant human factor IX: Replacement therapy, prophylaxis, pharmacokinetics, and immunogenicity in canine hemophilia B
5. Intratracheal administration of recombinant human factor IX (Benefix™) achieves therapeutic levels
6. Canine hemophilia B resulting from a point mutation with unusual consequences
7. In vivo gene therapy of hemophilia B: Sustained partial correction in factor IX-deficient dogs
8. Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill Colony
9. Development of a serum-free process for recombinant factor IX expression in Chinese hamster ovary cells
10. Development of a process for purification of recombinant human factor IX
11. Analytical characterization of recombinant human factor IX: Pharmacokinetic studies in the rat and the dog
12. Evaluation of recombinant human factor IX: Pharmacokinetic studies in the rat and the dog
13. A clinical study of the coagulation time of blood
14. Evaluation of sensitivity of whole blood clotting time (WBCT), partial thromboplastin time (PTT), and F.IX one-stage bioassay tests with low plasma F.IX levels observed with transfusion or gene therapy in canine hemophilia B
15. A role for whole blood clotting time as a sensitive screening test for F.VIII and F.IX replacement
16. Novel deconvolution method for linear pharmacokinetic systems with polyexponential impulse response
17. Subcutaneous injection of factor IX for the treatment of haemophilia B
18. Subcutaneous bioavailability of recombinant factor IX (BeneFix™) in healthy beagle dogs and cynomolugus monkeys
19. Identification of the endothelial cell binding site for factor IX
20. Human factor IX binds to specific sites on the collagenous domain of collagen IV
21. Subcutaneous recombinant factor IX (BeneFIX™) administration produces therapeutic levels of FIX activity in hemophilia B dogs
22. Pulmonary drug delivery: Physiologic and mechanistic aspects
23. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation
24. The pharmacokinetics of pulmonary-delivered insulin: A comparison of intratracheal and aerosol administration to the rabbit
25. Pulmonary metabolism of exogenous enkephalins in isolated perfused rat lungs
26. Delivery and retention of an insulin aerosol produced by a new jet nebulizer
27. An exploration of intrapulmonary insulin administration in anaesthetized and mechanically ventilated pigs
28. Preliminary study of the efficacy of insulin aerosol delivery by oral inhalation in diabetic patients
29. Pulmonary delivery of human protein C and factor IX
30. Insulin across respiratory mucosae by aerosol delivery